Stock Screener App

Gratuito -

Installare

11.02

0.27% 0.03

Keros Therapeutics Inc (KROS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché KROS Giù? Forum Previsione

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

Keros Therapeutics (NASDAQ:KROS) Gains Market Attention In Nasdaq Index - Kalkine Media

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart

Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com

Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan

Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily

Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart

Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times

Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView

Personalized ALS trial to test Keros rinvatercept at Mass General - Stock Titan

Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat

Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail

Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat

Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn

Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir

Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget

What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks

Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat

Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus

Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget

Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan

Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan

Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks

Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire

KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI

Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - MarketBeat

Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily

Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews

Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat

Keros Therapeutics adds former Lyell CFO to board By Investing.com - Investing.com India

Keros Therapeutics Adds Veteran Finance Leader to Board - TipRanks

Keros Therapeutics adds former Lyell CFO to board - Investing.com

Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan

Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant - Stock Titan

Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan

Keros Therapeutics (NASDAQ: KROS) grants CSO 75,000 options - Stock Titan

Keros Therapeutics Appoints Charles Newton to its Board of Directors - GlobeNewswire

KROS Technical Analysis & ETF Price Forecast - Intellectia AI

Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan

Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru

Tax-withholding stock sale by Keros (KROS) SVP and General Counsel Esther Cho - Stock Titan

Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn

Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times

Keros Therapeutics CEO to Present at Multiple Conferences - TipRanks

Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView

Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan

Sentiment Recap: Can Keros Therapeutics Inc weather a recessionQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView

Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

RPRX

$45.65

0.48%

ROIV

$28.06

1.72%

MRNA

$52.56

1.55%

BNTX

$91.19

1.21%

INSM

$139.50

0.01%

ONC

$284.05

0.44%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters